Long‐term treatment of prostate cancer with a well‐chosen treatment algorithm while maintaining a good quality of life

02/2018

MUDr. Adam Guňka, MUDr. Markéta Pospíšková, MUDr. Milan Kohoutek

Komplexní onkologické centrum Krajské nemocnice T. Bati, a.s., Zlín

SUMMARY

Prostate cancer is after lung cancer the most common type of malignant tumor in the male population worldwide. We can gradually decrease the number of lung patients by educating the population and using anti-smoking campaigns and hopefully the incidence and prevalence of the illness can be changed in the future. The probability of prostate cancer rises with age. Despite frequent occurrence this disease is not one of the diagnoses with poor prognosis depending on incidence. 80% of the patients are diagnosed with the disease which is not locally advanced and there is approximately 95% survival rate that the patients would live up to five years. This is not only thanks to early diagnosis but also thanks to new medications available in clinical practice. In Hormone-Dependent Prostate Cancer, the development of  hormone-resistant disease can be delayed by an average of three years by the luteinizing hormone-releasing hormone analog. Subsequently, the inclusion of androgen receptor targeted agents in the therapeutic algorithm of cast rationally-resistant prostate cancer has brought great advances in the treatment. Also, we cannot forget about the chemotherapy systematic treatment for generalized carcinoma where, for example, the Tax 327 study in 2004 showed a significantly longer survival of docetaxel-treated patients in combination with prednisone against mitoxantrone with prednisone.²

KEY WORDS

hormone-dependent prostate cancer, hormone-resistant prostate cancer, ARTA drugs, chemotherapy, treatment algorithm, quality of life